Here’s how analysts see FibroGen, Inc. (NASDAQ:FGEN) after this past week.

April 17, 2018 - By Michael Collier

FibroGen, Inc. (NASDAQ:FGEN) Ratings Coverage

Among 3 analysts covering FibroGen (NASDAQ:FGEN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. FibroGen had 3 analyst reports since October 18, 2017 according to SRatingsIntel. Leerink Swann maintained the stock with “Buy” rating in Wednesday, February 28 report. The rating was maintained by Mizuho with “Hold” on Thursday, March 29. The stock of FibroGen, Inc. (NASDAQ:FGEN) earned “Buy” rating by Stifel Nicolaus on Wednesday, October 18. Below is a list of FibroGen, Inc. (NASDAQ:FGEN) latest ratings and price target changes.

29/03/2018 Broker: Mizuho Rating: Hold New Target: $61.0000 Maintain
28/02/2018 Broker: Leerink Swann Rating: Buy New Target: $88.0 Maintain
18/10/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $80.0 Maintain

The stock increased 2.74% or $1.3 during the last trading session, reaching $48.7. About 149,119 shares traded. FibroGen, Inc. (NASDAQ:FGEN) has risen 78.19% since April 17, 2017 and is uptrending. It has outperformed by 66.64% the S&P500.

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. The company has market cap of $4.03 billion. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It currently has negative earnings. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.

FibroGen, Inc. (NASDAQ:FGEN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.